Skip to main content
Top
Published in: The European Journal of Health Economics 3/2011

Open Access 01-06-2011 | Original Paper

Practical issues in handling data input and uncertainty in a budget impact analysis

Authors: M. J. C. Nuijten, T. Mittendorf, U. Persson

Published in: The European Journal of Health Economics | Issue 3/2011

Login to get access

Abstract

The objective of this paper was to address the importance of dealing systematically and comprehensively with uncertainty in a budget impact analysis (BIA) in more detail. The handling of uncertainty in health economics was used as a point of reference for addressing the uncertainty in a BIA. This overview shows that standard methods of sensitivity analysis, which are used for standard data set in a health economic model (clinical probabilities, treatment patterns, resource utilisation and prices/tariffs), cannot always be used for the input data for the BIA model beyond the health economic data set for various reasons. Whereas in a health economic model, only limited data may come from a Delphi panel, a BIA model often relies on a majority of data taken from a Delphi panel. In addition, the dataset in a BIA model also includes forecasts (e.g. annual growth, uptakes curves, substitution effects, changes in prescription restrictions and guidelines, future distribution of the available treatment modalities, off-label use). As a consequence, the use of standard sensitivity analyses for BIA data set might be limited because of the lack of appropriate distributions as data sources are limited, or because of the need for forecasting. Therefore, scenario analyses might be more appropriate to capture the uncertainty in the BIA data set in the overall BIA model.
Literature
2.
go back to reference Drummond, et al.: Int. J. Technol. Ass. Health Care 24(3), 244–258 (2008) Drummond, et al.: Int. J. Technol. Ass. Health Care 24(3), 244–258 (2008)
3.
go back to reference Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth Department, Canberra (1992) Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth Department, Canberra (1992)
4.
go back to reference Detsky, A.S.: Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 3, 345–361 (1993)CrossRef Detsky, A.S.: Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 3, 345–361 (1993)CrossRef
5.
go back to reference Graf von der Schulenburg, J.M., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., Rebscher, H., Schoeffski, O., Vauth, C., Volmer, T., Wahler, S., Wasem, J., Weber, C., the Hanover Consensus Group: German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health 11(4), 539–544 (2008)PubMedCrossRef Graf von der Schulenburg, J.M., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., Rebscher, H., Schoeffski, O., Vauth, C., Volmer, T., Wahler, S., Wasem, J., Weber, C., the Hanover Consensus Group: German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health 11(4), 539–544 (2008)PubMedCrossRef
6.
go back to reference Mauskopf, J.A., Sullivan, S.D., Annemans, L., Caro, J., Mullins, C.D., Nuijten, M., Orlewska, E., Watkins, J., Trueman, P.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health 10(5), 336–347 (2007)PubMedCrossRef Mauskopf, J.A., Sullivan, S.D., Annemans, L., Caro, J., Mullins, C.D., Nuijten, M., Orlewska, E., Watkins, J., Trueman, P.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health 10(5), 336–347 (2007)PubMedCrossRef
7.
go back to reference Weinstein, M.C., Fineberg, H.V.: Clinical Decision Analysis, pp. 228–265. Saunders, Philadelphia (1980) Weinstein, M.C., Fineberg, H.V.: Clinical Decision Analysis, pp. 228–265. Saunders, Philadelphia (1980)
8.
go back to reference Nuijten, M.J., Rutten, F.: Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 20(12), 855–867 (2002)PubMedCrossRef Nuijten, M.J., Rutten, F.: Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 20(12), 855–867 (2002)PubMedCrossRef
9.
go back to reference Critchfield, G., Willard, K., Conelly, D.: Probabilistic sensitivity analysis methods for general decision models. Comput. Biomed. Res. 19, 254–265 (1986)PubMedCrossRef Critchfield, G., Willard, K., Conelly, D.: Probabilistic sensitivity analysis methods for general decision models. Comput. Biomed. Res. 19, 254–265 (1986)PubMedCrossRef
10.
go back to reference Doubilet, P., Begg, C.B., Weinstein, M.C., et al.: Probabilistic sensitivity analysis using Monte Carlo simulation. Med. Decis. Mak. 5, 157–177 (1985)CrossRef Doubilet, P., Begg, C.B., Weinstein, M.C., et al.: Probabilistic sensitivity analysis using Monte Carlo simulation. Med. Decis. Mak. 5, 157–177 (1985)CrossRef
12.
go back to reference Survey use of biologicals. Ars Accessus Medica (2008) Survey use of biologicals. Ars Accessus Medica (2008)
14.
go back to reference Van den Bemt, B.J.F., Hegeman, J., Janknegt, R., Van den Hoogen, F.H., Benraad, H.B., Van Limbeek, J.: Variability in dosing and costs of the TNFA-antagonists adalimumab and etanercept in patients with inflammatory rheumatic diseases. Ann. Rheum. Dis. 65(Suppl II), 507 (2006) Van den Bemt, B.J.F., Hegeman, J., Janknegt, R., Van den Hoogen, F.H., Benraad, H.B., Van Limbeek, J.: Variability in dosing and costs of the TNFA-antagonists adalimumab and etanercept in patients with inflammatory rheumatic diseases. Ann. Rheum. Dis. 65(Suppl II), 507 (2006)
15.
go back to reference Nuijten, M.J.C., Engelfriet, P., Duijn, K., Bruijn, G., Wierz, D., Koopmanschap, M.: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19(10), 1051–1064 (2001)PubMedCrossRef Nuijten, M.J.C., Engelfriet, P., Duijn, K., Bruijn, G., Wierz, D., Koopmanschap, M.: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19(10), 1051–1064 (2001)PubMedCrossRef
16.
go back to reference Lipsey, R., Steiner, P., Purvis, D., et al.: Economics, 9th edn. Harper and Row, New York (1990) Lipsey, R., Steiner, P., Purvis, D., et al.: Economics, 9th edn. Harper and Row, New York (1990)
Metadata
Title
Practical issues in handling data input and uncertainty in a budget impact analysis
Authors
M. J. C. Nuijten
T. Mittendorf
U. Persson
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 3/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0236-4

Other articles of this Issue 3/2011

The European Journal of Health Economics 3/2011 Go to the issue